Incyte (INCY) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $23.75B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William J. Meury |
| IPO Date | 1993-11-04 | CAGR | 35.62% |
| Employees | 2,844 | Website | www.incyte.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $19.67B | P/E | 15.98 | Forward P/E | 13.19 | PEG | 0.2 |
| P/S | 185.84 | P/B | 178.94 | P/CF | 654.69 | P/FCF | 686.21 |
| Sales | $5.36B | Sales 1Y | 21.48% | Sales 3Y | 54.49% | Sales 5Y | 98.34% |
| EPS | $7.44 | EPS 1Y | 2112.5% | EPS 3Y | 389.56% | EPS 5Y | 226.19% |
| Sales QoQ | -15.54% | EPS QoQ | 0.68% | Sales QoQ Avg | 5.65% | EPS QoQ Avg | 32.08% |
| Gross Margin | 92.48% | Operating Margin | 27.05% | Profit Margin | 26.71% | ROCE | 24.79% |
| ROA | 20% | ROE | 29% | Altman Z Score | 10.26 | Piotroski Score | 5 |
| Current Ratio | 3.68 | Quick Ratio | 3.6 | Cash Ratio | 2.32 | Op. CF Ratio | 0.25 |
| Debt/Equity | 0.01 | Debt/Assets | 0 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | — |
| Intrst Cov. | 620.56 | Inventory Turnover | 3.49 | Asset Turnover | 0.73 | Receivables Turnover | 5.1 |
| Enterprise Value | $19.67B | P/E Ratio | 15.98 |
| Forward P/E | 13.19 | PEG Ratio | 0.2 |
| P/S Ratio | 185.84 | P/B Ratio | 178.94 |
| P/CF Ratio | 654.69 | P/FCF Ratio | 686.21 |
| EPS | $7.44 | EPS Growth 1Y | 2112.5% |
| EPS Growth 3Y | 389.56% | EPS Growth 5Y | 226.19% |
| Revenue Growth 1Y | 21.48% | Gross Margin | 0.92% |
| Operating Margin | 0.27% | Profit Margin | 0.27% |
| ROE | 0.29% | ROA | 0.2% |
| ROCE | 0.25% | Current Ratio | 3.68 |
| Quick Ratio | 3.6 | Cash Ratio | 2.32 |
| Debt/Equity | 0.01 | Interest Coverage | 620.56 |
| Altman Z Score | 10.26 | Piotroski Score | 5 |
Incyte (INCY) valuation & financials
Incyte (INCY) has a market capitalization of $23.75B and trades at a price-to-earnings ratio of 16.0. It operates in the Healthcare sector (Biotechnology).
Incyte's revenue grew +21.5% over the last year.
Incyte's next earnings report is scheduled for July 28, 2026 before market open; analysts estimate EPS of $2.04.
Incyte (INCY) — frequently asked questions
When does Incyte (INCY) report earnings next?
Incyte is expected to report earnings on July 28, 2026 before market open. Analysts estimate EPS of $2.04.
What is Incyte's market cap?
Incyte (INCY) has a market capitalization of $23.75B.
What is INCY's P/E ratio?
Incyte trades at a price-to-earnings ratio of 16.0, with trailing twelve-month EPS of $7.44.
How fast is Incyte growing?
Incyte's revenue grew +21.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)